Biodexa To Present Recruitment And Treatment Update In Phase 1 Study Of MTX-110 In Patients With Recurrent Glioblastoma At 2023 Annual European Association Of Neuro-Oncology Meeting
Portfolio Pulse from Happy Mohamed
Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) will present an update on the recruitment and treatment of patients in the ongoing Phase 1 study of MTX-110 in patients with recurrent glioblastoma at the 2023 annual EANO meeting. So far, three patients have been dosed in the first cohort of the study with no observed dose-limiting toxicities. The study aims to assess the feasibility and safety of intermittent infusions of MTX-110 administered via implanted refillable pump and catheter.
September 21, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Biodexa Pharmaceuticals is making progress in its Phase 1 study of MTX-110 for the treatment of recurrent glioblastoma. No dose-limiting toxicities have been observed, which is a positive signal for the continuation of the drug's development.
The news of Biodexa's progress in its Phase 1 study of MTX-110 is likely to be viewed positively by investors. The absence of dose-limiting toxicities is a good sign for the drug's safety profile, which could increase its chances of regulatory approval and market success. This could potentially lead to an increase in Biodexa's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100